<DOC>
	<DOCNO>NCT00536120</DOCNO>
	<brief_summary>The primary objective study : evaluate effect TysabriÂ® ( natalizumab ) antibody responses immunization neoantigen ( keyhole limpet hemocyanin [ KLH ] ) recall antigen ( tetanus toxoid [ Td ] ) , evaluate effect Tysabri circulate lymphocyte subset ( CD3+ , CD4+ , CD8+ , CD19+ , CD56+ ) time participant relapse form multiple sclerosis ( MS ) . The secondary objective ass alpha4-integrin saturation alpha4-integrin expression level time .</brief_summary>
	<brief_title>The Effects Tysabri Treatment Vaccination Response Lymphocyte Subsets Subjects With Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>able give write informed consent diagnosis relapse form MS must fall within therapeutic indication state approved label Tysabri age 1860 year , inclusive time consent free sign symptom suggestive serious opportunistic infection , base medical history , physical examination , laboratory test must know history tetanus toxoid immunization Major tetanus toxoid vaccination le 2 year prior Screening know hypersensitivity tetanusdiphtheria vaccine KLH administer vaccination component ( thimerosal ) know allergy shellfish history active tuberculosis undergo treatment tuberculosis previous exposure KLH vaccine contain KLH component ( e.g. , cancer vaccine ) know history human immunodeficiency virus ( HIV ) , hepatitis C , hepatitis B infection history , available abnormal laboratory result indicative significant disease history malignancy history organ transplantation ( include antirejection therapy ) history severe allergic anaphylactic reaction know drug hypersensitivity clinically significant infectious illness within 30 day prior Screening visit prior exposure Tysabri , rituximab , murine protein , therapeutic monoclonal antibody time receipt intravenous ( IV ) intramuscular ( IM ) immunoglobulin within 6 month screen live virus , bacterial vaccine , vaccine within 3 month screen treatment immunosuppressant medication within 6 month prior screen treatment cyclophosphamide within 1 year prior screen treatment immunomodulatory medication ( interferon beta glatiramer acetate ) within 2 week prior screen treatment systemic corticosteroid within 4 week prior screen treatment investigational product approve therapy vaccination investigational use within 6 month prior Screening woman breastfeed , pregnant , plan become pregnant study female subject postmenopausal least 1 year , surgically sterile ( include tubal ligation ) , willing practice effective contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Relapsing form Multiple Sclerosis</keyword>
</DOC>